Get the Stockscreener App
4.26
2.40%
0.10
After Hours:
4.26
4 D Molecular Therapeutics Inc stock is traded at $4.26, with a volume of 319.59K.
It is up +2.40% in the last 24 hours and down -2.52% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$4.16
Open:
$4.2
24h Volume:
319.59K
Relative Volume:
0.70
Market Cap:
$197.34M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-1.6015
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-3.62%
1M Performance:
-2.52%
6M Performance:
-8.97%
1Y Performance:
-84.07%
1-Day Range:
$4.20
$4.3385
1-Week Range:
$4.11
$4.50
52-Week Range:
$2.235
$28.93
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
4.26 | 195.49M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.40 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.77 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
What makes 4D Molecular Therapeutics Inc. stock price move sharplyHigh Return Potential - Newser
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attentionFree Signals Group - Newser
How 4D Molecular Therapeutics Inc. stock performs during market volatilityAI Powered Stock Call - Newser
Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Late-Stage Biotech 4DMT Grants Significant RSU Package in Latest Strategic Hire - Stock Titan
4D Molecular to layoff about 25% of workforce - MSN
Promising Penny Stocks To Consider In July 2025 - simplywall.st
Chardan Capital Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
What 4 Analyst Ratings Have To Say About 4D Molecular Therapeutics - Nasdaq
East Bay biotech to slash 25% of jobs after launching 2nd late-stage eye gene therapy study - The Business Journals
4D Molecular Therapeutics Accelerates Wet AMD Trial, Cuts Jobs to Offset Costs - MarketScreener
4DMT Announces Accelerated 4D-150 Phase 3 Development in - GlobeNewswire
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) dropped from Russell Microcap Growth Index - MarketScreener
Weiss Ratings Reaffirms Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED
Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com
Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World
Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World
Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times
Cantor Fitzgerald Forecasts UTHR FY2026 Earnings - Defense World
Cantor Fitzgerald Forecasts UBER FY2026 Earnings - Defense World
Cantor Fitzgerald Forecasts TYL FY2026 Earnings - Defense World
Analysts Set Expectations for SHLS FY2026 Earnings - Defense World
Equities Analysts Offer Predictions for VYGR FY2026 Earnings - Defense World
Cantor Fitzgerald Predicts TG Therapeutics FY2026 Earnings - Defense World
Analysts Set Expectations for SLNO FY2026 Earnings - Defense World
Equities Analysts Offer Predictions for SPWR FY2026 Earnings - Defense World
Brokers Set Expectations for XENE FY2026 Earnings - Defense World
Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
ProShare Advisors LLC Increases Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Bank of America Corp DE Buys 127,885 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Two Sigma Investments LP Acquires 208,021 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Tesco (LON:TSCO) Stock Crosses Above 200-Day Moving Average – Should You Sell? - Defense World
Telsey Advisory Group Forecasts Macy’s’ Q2 Earnings (NYSE:M) - Defense World
D. E. Shaw & Co. Inc. Purchases 12,217 Shares of Arcos Dorados Holdings Inc. (NYSE:ARCO) - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lowered by D. E. Shaw & Co. Inc. - Defense World
4DMT to Participate in Upcoming Investor Conferences | FDMT Stock News - GuruFocus
4DMT to Participate in Upcoming Investor Conferences - Eagle-Tribune
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World
Millennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progress - Investing.com
Deutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.38%
2.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):